Abstract
A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Current Radiopharmaceuticals
Title:A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation
Volume: 6 Issue: 1
Author(s): Ling Qiu, Wen Cheng, Jianguo Lin, Shu Zhang and Shineng Luo
Affiliation:
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Abstract: A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Export Options
About this article
Cite this article as:
Qiu Ling, Cheng Wen, Lin Jianguo, Zhang Shu and Luo Shineng, A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation, Current Radiopharmaceuticals 2013; 6 (1) . https://dx.doi.org/10.2174/1874471011306010005
DOI https://dx.doi.org/10.2174/1874471011306010005 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Obesity in China: What are the Causes?
Current Pharmaceutical Design The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe
Current Drug Metabolism Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Single-cell Sequencing in the Field of Stem Cells
Current Genomics Therapy of Hepatocellular Carcinoma with Rhenium-188 Lipiodol
Current Radiopharmaceuticals ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Interventional Radiology in Paediatrics
Current Pediatric Reviews Gender Effects on Rat Metabolism of AMG 900, an Orally Available Small Molecule Aurora Kinase Inhibitor
Drug Metabolism Letters Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design Antinociceptive Effects of VV-Hemorphin-5 Peptide Analogues Containing Amino phosphonate Moiety in Mouse Formalin Model of Pain
Protein & Peptide Letters Prokaryotic Arsenate Reductase Enhances Arsenate Resistance in Mammalian Cells
Recent Patents on Food, Nutrition & Agriculture Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Role of Radiopharmaceuticals in Development of Inhaled Drugs
Current Pharmaceutical Design